Evidence-Based Complementary and Alternative Medicine better and costs less than conventional medicine for the management of common diseases [14]. Blood pressure regulation involves multiple system inter- action, such as kidneys, central nervous system (CNS), peripheral nervous system (PNS), and endothelial system. Hypertension is caused by a variety of factors such as the interaction of environment and heredity factors leading to disturbances of blood pressure regulation, the pathological mechanism of which includes sympathetic nervous system (SNS), renin-angiotensin-aldosterone system (RAAS), vaso- pressin (VP), nitric oxide (NO), endothelin (ET), adrenal medulla, and a variety of vasoactive peptide secreted by other endothelial cells and smooth muscle cells [15–17]. Although hypertension is a common cardiovascular disease, it is always combined with hyperlipidemia, coronary heart disease, diabetes, metabolic syndrome, and other diseases, which involve the cardiovascular, endocrine, neurologic, renal medicine, and other departments. Therefore, hypertension is a chronic and complex disease relating to systemic multiple systems. Besides lowering blood pressure steadily, the ﬁnal purpose of Chinese medicine in treating hypertension is to reduce blood pressure variability and risk factors, protect hypertension target organs from the impairment, modulate factors diﬃcult to control blood pressure, reduce the dosage of western medicine and abate the adverse reactions, relieve symptoms to improve patients’ quality of life, improve long-term survival, and reduce the morbidity and mortality maximally [18]. It may be just what the scholars of Chinese medicine need to focus on, reﬂecting the advantages of Chinese medicine treatment. Although antihypertensive drugs have great advantage in reducing blood pressure rapidly with reliable eﬀect, Chinese medicine can work at diﬀerent levels and targets quite diﬀerent from western drug which works relatively at few targets [19]. Researches had shown that Chinese herbs can regulate the function of RAAS, sympathetic-vagus nerve, and immune system, inhibit the level of inﬂammatory factor, pre- vent and reverse left ventricular hypertrophy caused by high blood pressure, inﬂuence vasoactive substances signiﬁcantly, and so on [20–23]. Professor Li had observed the eﬀect of Chinese medicine, Jiangya capsules, which was made up of Radix Cyathulae, Radix Achyranthis Bidentatae, Pheretima, Laminaria japonica, Rhizoma Gastrodiae, Rhizoma Chuanx- iong, and so on, with multicenter, randomized, double- blind, positive controlled clinical design in elderly patients with isolated systolic hypertension (EISH). It showed that Chinese medical regimen had aﬃrmative eﬀect in treating EISH patients and could lower the systolic blood pressurea and improve quality of life and early renal impairment of the patients [24]. Professor Zhou found out that combined use of Xuezhikang or pravastatin with the antihypertensive therapy could increase the circulating endothelial progen- itor cells number and improve their function in essential hypertensive patients with the blood pressure controlled by antihypertensive drugs, leading to beneﬁts independent of pressure-lowering eﬀects [25]. Furthermore, we found that there are laws for treatment according to many of years experience of large number of patients with hypertension. It has important signiﬁcance 5 in carefully analyzing common symptoms of hypertension, the etiology and pathogenesis, formula syndrome rules, herb syndrome rules, dose rules, combined diseases, and uncontrollable factors of blood pressure under the guidance of theory of Chinese medicine [26, 27]. Conﬂict of Interests All authors manifest that there is no conﬂict of interests. Acknowledgments The current work was partially supported by the National Basic Research Program of China (973 Program, no. 2003CB517103) and the National Natural Science Foun- dation Project of China (no. 90209011). The ﬁrst author, Professor J. Wang, M. D., and the correspondence author, X. Xiong, M. D., contributed equally in this paper. References [1] Cardiology Branch of Chinese Medical Association, Treatment Guidelines and Recommendations of Cardiovascular Disease, People’s Military Medical Press, Beijing, China, 2005. [2] H. Redwood, “Hypertension, society, and public policy,” European Heart Journal, vol. 9, supplement B, pp. B13–B18, 2007. [3] L. Z. Kong and S. S. Hu, Cardiovascular Report 2006 in China, Encyclopedia of China Publishing House, Beijing, China, 2008. [4] H. Xu and K. J. Chen, “Progress, diﬃculty and countermea- sure in treating hypertensive disease with integrated Chinese and Western medicine,” Shi Jie Zhong Yi Yao, vol. 2, no. 1, pp. 3–5, 2007. [5] K. J. Chen, “Research on hypertension with integrated Chinese and Western Medicine,” Zhong Guo Zhong Xi Yi Jie He Za Zhi, vol. 30, no. 5, p. 453, 2010. [6] L. Y. Wang, Y. Li, N. Li, Y. Ding, N. N. Shi, and X. J. Han, “Study on TCM syndrome distribution of 1508 cases of hypertension patients with clinical epidemiology,” Zhong Hua Zhong Yi Yao Za Zhi, vol. 25, no. 12, pp. 1960–1963, 2010. [7] H. Huang, Huang Huang’s Use Manual of Classical Prescription, Chinese Medicine Publishing House, Beijing, China, 2010. [8] Y. H. Xie, J. C. Zhang, Y. R. Jiang et al., “Data-mining of clinical hypertensive cases from Dr. Chen Keji,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 6, no. 2, pp. 135–136, 2008. [9] N. Robinson, “Integrative medicine—traditional Chinese medicine, a medel?” Chinese Journal of Integrative Medicine, vol. 17, no. 1, pp. 21–25, 2011. [10] H. R. Schumacher, “West meets East—observations on inte- grative medicine in rheumatology from the USA,” Chinese Journal of Integrative Medicine, vol. 14, no. 3, pp. 165–166, 2008. [11] S. Grace and J. Higgs, “Integrative medicine: enhancing quality in primary health care,” Journal of Alternative and Complementary Medicine, vol. 16, no. 9, pp. 945–950, 2010. [12] H. S. Boon and N. Kachan, “Integrative medicine: a tale of two clinics,” BMC Complementary and Alternative Medicine, vol. 8, article 32, 2008.